IL1B and cystinosis: Prencipe et al. targeted the activated NLRP3 inflammasome pathway in cystinosis through the cathepsin B inhibitors CA-074Me and diphenyleneiodonium chloride, which decreased the secretion of IL-1β induced by the cystine crystals in the peripheral blood monocytes and suppressing the inflammatory cascade that should follow, thereby paving the way for another mechanism that can be targeted in cystinosis patients [18].